Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -45

Bristol Myers vs. Novo Nordisk: Both Trade Cheap, and the Discounts ...

Drug pricing Earnings report AI-generated analysis

πŸ“‰ NVO trades near $39 at a 9.5x forward multiple, reflecting market pricing of flat earnings and stagnant growth expectations through 2030.

πŸ’Š U.S. list prices for Wegovy and Ozempic dropped from over $1,000 to $350 due to federal retail channel agreements, driving a 15% decline in prescription volumes.

πŸ“‰ Management has explicitly guided for operating margins to remain broadly stable through 2030 rather than expanding despite the company's dominant market position.

πŸ’° Citi estimates U.S. Ozempic prescription volumes have fallen roughly 15%, with third-quarter sales forecast down about 4% in constant currency.

πŸš€ The oral obesity pipeline shows promise internationally, with peak sales estimates raised to $13 billion and strong early efficacy data for amycretin.

πŸ“‰ Analysts have trimmed expected EPS growth from 12% to 9% for the 2027-2030 period due to the structural nature of the pricing squeeze.

βš–οΈ The stock is viewed as a high-risk lottery ticket with enormous upside potential contingent on pipeline success rather than a safe value play.

Bullish Signals
  • The oral version of Wegovy is gaining traction internationally, moving about one million packs through the U.K. since July.
  • Pipeline candidate amycretin reported approximately 13% weight loss at 12 weeks in early trials, roughly twice the efficacy of current Wegovy.
  • Another pipeline drug, CagriSema, demonstrated 22.7% weight loss at 68 weeks in Phase 3 data, validating the company's long-term obesity strategy.
Risk Factors
  • The company guided for a 5% to 13% decline in 2026 sales driven by U.S. pricing cuts rather than lost demand.
  • Management has committed to keeping operating margins broadly stable through 2030, signaling an end to the high-growth era.
  • Citi cut its target price and estimates that the structural pricing squeeze is not cyclical but a permanent headwind.
  • The market is pricing in flat earnings rather than a rebound, creating skepticism about the sustainability of current growth rates.
Full Analysis
Novo Nordisk (NVO) trades at a low forward multiple of approximately 9.5x earnings, reflecting market concerns over structural pricing pressures and stagnant growth expectations. The company recently guided for flat operating margins through 2030 following a significant U.S. price cut to its Wegovy and Ozempic products, which has already impacted prescription volumes and sales guidance for 2026. While Novo possesses substantial optionality in its oral obesity pipeline and late-stage candidates like amycretin, the market currently views these as unproven drivers of recovery rather than immediate earnings support. Analysts have trimmed growth estimates due to the combination of government-imposed price reductions and competition from rivals like Eli Lilly. The investment thesis for Novo Nordisk hinges on whether the current low valuation represents a temporary trough or a long-term value trap given the company's own cautious guidance. Unlike peers with scheduled patent cliffs, Novo faces ongoing margin compression that requires successful pipeline validation to justify its discount and restore growth trajectory.